Table 2.

Clinicopathologic characteristics of patients

Variable	Total, N	No complication group, N (%)	Complication group, N (%)	p
Number of Patients	1081	1022 (94.5)	59 (5.5)
Location				0.032
Right	514	484 (94.2)	30 (5.8)
Left	499	478 (95.8)	21 (4.2)
Bilateral	68	60 (88.2)	8 (11.8)
Histopathology				0.939
Invasive cancer	841	794 (94.4)	47 (5.6)
DCIS	199	189 (95.0)	10 (5.0)
Other	41	39 (95.1)	2 (4.9)
Nuclear grade				0.966
Low	153	144 (94.1)	9 (5.9)
Intermediate	663	627 (94.6)	36 (5.4)
High	265	251 (94.7)	14 (5.3)
LVI				0.001
Yes	285	258 (90.5)	27 (9.5)
No	796	764 (96.0)	32 (4.0)
Pathologic T				0.118
Tis & pCR	212	207 (97.6)	5 (2.4)
T1	514	484 (94.2)	30 (5.8)
T2	299	280 (93.6)	19 (6.4)
≥ T3	56	51 (91.1)	5 (8.9)
Pathologic N				< 0.001
N0	795	768 (96.6)	27 (3.4)
N1	227	208 (91.6)	19 (8.4)
N2	42	33 (78.6)	9 (21.4)
N3	17	13 (76.5)	4 (23.5)
Pathologic prognostic stage				0.017
0 & NRT	207	199 (96.1)	8 (3.9)
I	456	431 (94.5)	25 (5.5)
II	342	326 (95.3)	16 (4.7)
III	76	66 (86.8)	10 (13.2)
ER				0.445
Positive	895	844 (94.3)	51 (5.7)
Negative	186	178 (95.7)	8 (4.3)
PR				0.192
Positive	842	792 (94.1)	50 (5.9)
Negative	239	230 (96.2)	9 (3.8)
C-erbB-2				0.586
Positive	296	280 (94.6)	16 (5.4)
Negative	664	630 (94.9)	34 (5.1)
Unknown	121	112 (92.6)	9 (7.4)
Subtype				0.880
HR (+)	900	849 (94.3)	51 (5.7)
HR(−) C-erbB-2(+)	121	116 (95.9)	5 (4.1)
HR(−) C-erbB-2(−)	56	53 (94.6)	3 (5.4)
Unknown	4	4 (100.0)	0 (0.0)

DCIS Ductal carcinoma in situ, LVI Lymphovasvular invasion, pCR Pathologic complete response, NRT No residual tumor, HR Hormonal receptor